UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Liver international, 2019-08, Vol.39 (8), p.1468-1477

2019

Volltextzugriff (PDF)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Journal for immunotherapy of cancer, 2021-03, Vol.9 (3), p.e002068

2021

Volltextzugriff (PDF)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

BMC cancer, 2023-07, Vol.23 (1), p.708-708, Article 708

2023

Volltextzugriff (PDF)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Cancer medicine (Malden, MA), 2021-05, Vol.10 (9), p.3059-3067

2021

Volltextzugriff (PDF)

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Volltextzugriff (PDF)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

British journal of cancer, 2018-11, Vol.119 (10), p.1208-1214

2018

Volltextzugriff (PDF)

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Journal of clinical oncology, 2021-04, Vol.39 (10), p.1108-1118

2021

Volltextzugriff (PDF)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Volltextzugriff (PDF)

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

Clinical cancer research, 2015-02, Vol.21 (3), p.553-560

2015

Volltextzugriff (PDF)

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-08, Vol.18 (8), p.1146-1156

2016

Volltextzugriff (PDF)

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer's & dementia, 2023-06, Vol.19 (S7), p.n/a

2023

Volltextzugriff (PDF)

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Clinical cancer research, 2019-12, Vol.25 (23), p.6976-6985

2019

Volltextzugriff (PDF)

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.95-103

2016

Volltextzugriff (PDF)

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Alzheimer's & dementia, 2023-06, Vol.19 (6), p.2253-2264

2023

Volltextzugriff (PDF)

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

European journal of pharmaceutical sciences, 2021-06, Vol.161, p.105781-105781, Article 105781

2021

Volltextzugriff (PDF)

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2015-12, Vol.76 (6), p.1143-1152

2015

Volltextzugriff (PDF)

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Volltextzugriff (PDF)

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Volltextzugriff (PDF)

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA

Neuro-oncology (Charlottesville, Va.), 2016-11, Vol.18 (suppl_6), p.vi4-vi4

2016

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Journal of thoracic oncology, 2021-02, Vol.16 (2), p.327-333

2021

Volltextzugriff (PDF)

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Volltextzugriff (PDF)

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Molecular pharmaceutics, 2015-04, Vol.12 (4), p.1131-1140

2015

Volltextzugriff (PDF)

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Xenobiotica, 2018-04, Vol.48 (4), p.382-399

2018

Volltextzugriff (PDF)

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

British journal of clinical pharmacology, 2014-05, Vol.77 (5), p.796-807

2014

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

ThemaPharmacodynamics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(63)
Dissertationen
(1)

Sprache

Englisch
(64)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

ACTR-16. PHASE 2 STUDY EVALUATING SAFETY, PHARMACOKINETICS (PK), PHARMACODYNAMICS (PD) AND EFFICACY OF THE ORAL TRANSFORMING GROWTH FACTOR-BETA (TGF-β) RECEPTOR I KINASE INHIBITOR GALUNISERTIB WHEN COMBINED WITH CHEMORADIOTHERAPY IN NEWLY DIAGNOSED MALIGNANT GLIOMA

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Defining a therapeutic window for the novel TGF‐β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Aktive Filter

Suchergebnisse filtern